Chuantao Ye, Zhuoran Xiao, Mengyuan Li, Min Wei, Xinyi Du, Jiaojiao Cao, Shasha Wu, RongRong Zhang, Xiaofei Yang, Chao Fan, Hong Du, Jing Zhang, Jianqi Lian
{"title":"Α Case of Severe Immune Deficiency and Encephalitis Associated With Human Herpesvirus-7 (HHV-7) Infection","authors":"Chuantao Ye, Zhuoran Xiao, Mengyuan Li, Min Wei, Xinyi Du, Jiaojiao Cao, Shasha Wu, RongRong Zhang, Xiaofei Yang, Chao Fan, Hong Du, Jing Zhang, Jianqi Lian","doi":"10.1002/jmv.70280","DOIUrl":"https://doi.org/10.1002/jmv.70280","url":null,"abstract":"","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Regarding the Article A Nomogram and Heat Map Based on LASSO-Cox Regression for Predicting the Risk of Early-Stage Severe Fever With Thrombocytopenia Syndrome Patients Developing Into Critical Illness at 7-Day and 14-Day by Tong et al.","authors":"Neng Wang, Shuai Tao, Liang Chen","doi":"10.1002/jmv.70291","DOIUrl":"https://doi.org/10.1002/jmv.70291","url":null,"abstract":"","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuan Zong, Koju Kamoi, Jing Zhang, Mingming Yang, Zou Yaru, Miki Miyagaki, Kyoko Ohno-Matsui
In aging societies, uveitis—a leading cause of vision loss due to ocular inflammation—is increasingly prevalent, especially among older people. This study aimed to determine the trends and contributing factors of herpetic uveitis in older people, reflecting the broader impact of demographic shifts on ocular health. A retrospective study at the Institute of Science Tokyo reviewed uveitis cases in patients aged ≥ 65 years between 2012 and 2022. Among the 1095 older patients diagnosed with uveitis, 65 (5.9%) had herpesvirus uveitis, predominantly manifesting as unilateral anterior uveitis, with cytomegalovirus as the most common virus. Male predominance in herpetic uveitis cases was identified. The study also noted a significantly higher incidence of unilateral onset in herpetic cases compared to non-herpetic ones (p < 0.05). There was a trend toward a higher rate of secondary glaucoma in herpetic cases. Post-2020, an upsurge in herpetic uveitis diagnoses was recorded, potentially linked to the immunosuppressive effects of the coronavirus disease 2019 pandemic. Additionally, rare and severe acute retinal necrosis was identified in the study cohort. These findings highlight the growing trend of herpetic uveitis in older people in Japan and emphasize the necessity for advanced monitoring, diagnostic accuracy, and treatment strategies for herpes uveitis in aging populations globally.
{"title":"The Silent Epidemic: Unveiling Herpetic Uveitis in the Elderly","authors":"Yuan Zong, Koju Kamoi, Jing Zhang, Mingming Yang, Zou Yaru, Miki Miyagaki, Kyoko Ohno-Matsui","doi":"10.1002/jmv.70286","DOIUrl":"https://doi.org/10.1002/jmv.70286","url":null,"abstract":"<div>\u0000 \u0000 <p>In aging societies, uveitis—a leading cause of vision loss due to ocular inflammation—is increasingly prevalent, especially among older people. This study aimed to determine the trends and contributing factors of herpetic uveitis in older people, reflecting the broader impact of demographic shifts on ocular health. A retrospective study at the Institute of Science Tokyo reviewed uveitis cases in patients aged ≥ 65 years between 2012 and 2022. Among the 1095 older patients diagnosed with uveitis, 65 (5.9%) had herpesvirus uveitis, predominantly manifesting as unilateral anterior uveitis, with cytomegalovirus as the most common virus. Male predominance in herpetic uveitis cases was identified. The study also noted a significantly higher incidence of unilateral onset in herpetic cases compared to non-herpetic ones (<i>p</i> < 0.05). There was a trend toward a higher rate of secondary glaucoma in herpetic cases. Post-2020, an upsurge in herpetic uveitis diagnoses was recorded, potentially linked to the immunosuppressive effects of the coronavirus disease 2019 pandemic. Additionally, rare and severe acute retinal necrosis was identified in the study cohort. These findings highlight the growing trend of herpetic uveitis in older people in Japan and emphasize the necessity for advanced monitoring, diagnostic accuracy, and treatment strategies for herpes uveitis in aging populations globally.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luisa Galati, Marta Tagliabue, Tarik Gheit, Rita De Berardinis, Fausto Maffini, Sandrine McKay-Chopin, Giuseppe De Palma, Stefania Vecchio, Angelo Virgilio Paradiso, Laura Sichero, Luisa Lina Villa, Francesco Chu, Francesco Bandi, Chiara Mossinelli, Jacopo Zocchi, Giacomo Pietrobon, Stefano Filippo Zorzi, Enrica Grosso, Stefano Riccio, Roberto Bruschini, Gioacchino Giugliano, Giovanni Blandino, Maria Lina Tornesello, Mohssen Ansarin, Massimo Tommasino, Susanna Chiocca
Oral HPV DNA and circulating tumor (ct) HPV DNA in plasma were evaluated as potential biomarkers for HPV-associated head and neck cancer (HNC). Samples from HNC patients (n = 132), including 23 oropharyngeal cancers (OPC), and non-HNC controls (n = 10) were analyzed. HPV status was determined using a multiplex bead-based test (E7-MPG) applied to formalin-fixed paraffin-embedded (FFPE) tissues (n = 90), plasma (n = 141), gargle samples (n = 141), and oral swabs (n = 142). HPV DNA was detected in 25.8% of HNC tissues, 12% of plasma samples, 20.6% of gargles and 7% of oral swabs with HPV16 as the most prevalent genotype. Among OPC cases, HPV16 DNA was found in 71.4% of FFPE samples. High concordance was observed between paired OPC tissues and plasma (91.3%) or gargles (95.2%), with moderate concordance for oral swabs (59.1%). Gargle samples alone demonstrated a 100% detection rate for HPV16-positive OPC, regardless of the cT stage, outperforming plasma (86.7%). Combined oral gargle and plasma analyses detected all HPV-positive OPC cases (7/7) at the early cT1 stage. These findings highlight the limited involvement of HPV in non-oropharyngeal HNC compared to OPC, and support gargle and plasma samples as minimally invasive diagnostic tools for detecting HPV-associated OPC.
{"title":"HPV Biomarkers in Oral and Blood-Derived Body Fluids in Head and Neck Cancer Patients","authors":"Luisa Galati, Marta Tagliabue, Tarik Gheit, Rita De Berardinis, Fausto Maffini, Sandrine McKay-Chopin, Giuseppe De Palma, Stefania Vecchio, Angelo Virgilio Paradiso, Laura Sichero, Luisa Lina Villa, Francesco Chu, Francesco Bandi, Chiara Mossinelli, Jacopo Zocchi, Giacomo Pietrobon, Stefano Filippo Zorzi, Enrica Grosso, Stefano Riccio, Roberto Bruschini, Gioacchino Giugliano, Giovanni Blandino, Maria Lina Tornesello, Mohssen Ansarin, Massimo Tommasino, Susanna Chiocca","doi":"10.1002/jmv.70278","DOIUrl":"https://doi.org/10.1002/jmv.70278","url":null,"abstract":"<div>\u0000 \u0000 <p>Oral HPV DNA and circulating tumor (ct) HPV DNA in plasma were evaluated as potential biomarkers for HPV-associated head and neck cancer (HNC). Samples from HNC patients (<i>n</i> = 132), including 23 oropharyngeal cancers (OPC), and non-HNC controls (<i>n</i> = 10) were analyzed. HPV status was determined using a multiplex bead-based test (E7-MPG) applied to formalin-fixed paraffin-embedded (FFPE) tissues (<i>n</i> = 90), plasma (<i>n</i> = 141), gargle samples (<i>n</i> = 141), and oral swabs (<i>n</i> = 142). HPV DNA was detected in 25.8% of HNC tissues, 12% of plasma samples, 20.6% of gargles and 7% of oral swabs with HPV16 as the most prevalent genotype. Among OPC cases, HPV16 DNA was found in 71.4% of FFPE samples. High concordance was observed between paired OPC tissues and plasma (91.3%) or gargles (95.2%), with moderate concordance for oral swabs (59.1%). Gargle samples alone demonstrated a 100% detection rate for HPV16-positive OPC, regardless of the cT stage, outperforming plasma (86.7%). Combined oral gargle and plasma analyses detected all HPV-positive OPC cases (7/7) at the early cT1 stage. These findings highlight the limited involvement of HPV in non-oropharyngeal HNC compared to OPC, and support gargle and plasma samples as minimally invasive diagnostic tools for detecting HPV-associated OPC.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70278","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hwee Sze Tee, Jingtong Liang, Norazlin Abdul Aziz, Xiang Zhou, Hamidah Akmal Hisham, Ke-En Tan, Yanhong Chen, Zuriani Burhanuddin, Johnny S. H. Kwan, Kwok-Wai Lo, Faridah Hassan, Sha'ariyah bt Mohd Mokhtar, Alan Soo Beng Khoo, Miao Xu, Yat-Yuen Lim, Lu Ping Tan
Epstein–Barr virus (EBV) is associated with cancers, including lymphomas and nasopharyngeal carcinoma (NPC). To date, risk variants for NPC were mainly identified from Chinese populations, which dominated the world's total number of cases. Although Southeast Asia (SEA) countries have among the world's top yet intriguingly diverse NPC age-standardized incidence rates across subpopulations, data on EBV from SEA remains scarce. In this study, we examined 83 NPC patients of different ancestries for the presence of risk haplotypes associated with the Southern Chinese NPC and generated and analyzed 67 EBV sequences (from tissue, patient-derived xenografts and lymphoblastoid cell lines of 60 NPC patients) together with 838 published EBV genomes. Our study revealed that NPC patients of non-Chinese ancestry had fewer risk variants and haplotypes that are associated with Southern Chinese NPC and clustered distinctly from lymphomas, Southern Chinese NPC, and non-cancer controls. The distribution of non-synonymous variants was similar among NPC patients of Chinese ancestry, irrespective of geographical location. Meanwhile, non-synonymous variants in genes related to packaging, latency, and structural proteins such as BPLF1, LF3, and LMP1 varied across different ancestries. Our findings suggest possibilities of EBV adaptation to host genetics for NPC pathogenesis and warrant further research for the understudied NPC subpopulations.
{"title":"Epstein–Barr Virus Sequence Variations Among the Understudied Nasopharyngeal Carcinoma Patients of Diverse Ancestries in Southeast Asia","authors":"Hwee Sze Tee, Jingtong Liang, Norazlin Abdul Aziz, Xiang Zhou, Hamidah Akmal Hisham, Ke-En Tan, Yanhong Chen, Zuriani Burhanuddin, Johnny S. H. Kwan, Kwok-Wai Lo, Faridah Hassan, Sha'ariyah bt Mohd Mokhtar, Alan Soo Beng Khoo, Miao Xu, Yat-Yuen Lim, Lu Ping Tan","doi":"10.1002/jmv.70269","DOIUrl":"https://doi.org/10.1002/jmv.70269","url":null,"abstract":"<p>Epstein–Barr virus (EBV) is associated with cancers, including lymphomas and nasopharyngeal carcinoma (NPC). To date, risk variants for NPC were mainly identified from Chinese populations, which dominated the world's total number of cases. Although Southeast Asia (SEA) countries have among the world's top yet intriguingly diverse NPC age-standardized incidence rates across subpopulations, data on EBV from SEA remains scarce. In this study, we examined 83 NPC patients of different ancestries for the presence of risk haplotypes associated with the Southern Chinese NPC and generated and analyzed 67 EBV sequences (from tissue, patient-derived xenografts and lymphoblastoid cell lines of 60 NPC patients) together with 838 published EBV genomes. Our study revealed that NPC patients of non-Chinese ancestry had fewer risk variants and haplotypes that are associated with Southern Chinese NPC and clustered distinctly from lymphomas, Southern Chinese NPC, and non-cancer controls. The distribution of non-synonymous variants was similar among NPC patients of Chinese ancestry, irrespective of geographical location. Meanwhile, non-synonymous variants in genes related to packaging, latency, and structural proteins such as <i>BPLF1</i>, <i>LF3</i>, and <i>LMP1</i> varied across different ancestries. Our findings suggest possibilities of EBV adaptation to host genetics for NPC pathogenesis and warrant further research for the understudied NPC subpopulations.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aims to assess the impact of recombinant zoster vaccine (RZV) on the risk of major cardiovascular events (MACE) in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), or psoriatic diseases who are receiving Janus kinase inhibitors (JAKi). We conducted a new user design study utilizing the TriNetX database. We identified patients diagnosed with RA, SpA, or psoriatic diseases receiving JAKi. Two cohorts were constructed based on RZV vaccination status. Propensity score matching was performed. The primary outcome was MACE, analyzed using Cox regression with hazard ratios (HR) and Kaplan−Meier plots. Subgroup analyses were performed by age, sex, race, and zoster history. Sensitivity analyses were conducted with different follow-up periods and diseases. Of the 1 528 771 eligible patients initially included, each cohort included 1756 patients after propensity score matching. No significant difference in MACE risk was observed between the two cohorts (HR 1.121, 95% CI: 0.901−1.395). Subgroup and sensitivity analyses were consistent with the main findings. However, RZV vaccination was associated with a significant reduction in all-cause mortality (HR 0.610, 95% CI: 0.427−0.870). Subgroup analyses indicated that the mortality benefit was particularly evident in females (HR 0.585, 95% CI: 0.379−0.901) and those aged 65 years and older (HR 0.500, 95% CI: 0.301−0.806). In patients with immune-mediated inflammatory diseases receiving JAKi, RZV vaccination is associated with a 39% reduction in all-cause mortality compared to unvaccinated individuals. RZV vaccination should be considered for this high-risk population.
{"title":"Recombinant Zoster Vaccine Reduces All-Cause Mortality, But Not Major Adverse Cardiovascular Events, in Patients With Immune-Mediated Inflammatory Diseases Receiving Janus Kinase Inhibitors: A Large-Scale Real-World Retrospective Cohort Study","authors":"Po-Cheng Shih, Shiow-Ing Wang, Pui-Ying Leong, An-Ping Huo, James Cheng-Chung Wei","doi":"10.1002/jmv.70285","DOIUrl":"https://doi.org/10.1002/jmv.70285","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 <p>This study aims to assess the impact of recombinant zoster vaccine (RZV) on the risk of major cardiovascular events (MACE) in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), or psoriatic diseases who are receiving Janus kinase inhibitors (JAKi). We conducted a new user design study utilizing the TriNetX database. We identified patients diagnosed with RA, SpA, or psoriatic diseases receiving JAKi. Two cohorts were constructed based on RZV vaccination status. Propensity score matching was performed. The primary outcome was MACE, analyzed using Cox regression with hazard ratios (HR) and Kaplan−Meier plots. Subgroup analyses were performed by age, sex, race, and zoster history. Sensitivity analyses were conducted with different follow-up periods and diseases. Of the 1 528 771 eligible patients initially included, each cohort included 1756 patients after propensity score matching. No significant difference in MACE risk was observed between the two cohorts (HR 1.121, 95% CI: 0.901−1.395). Subgroup and sensitivity analyses were consistent with the main findings. However, RZV vaccination was associated with a significant reduction in all-cause mortality (HR 0.610, 95% CI: 0.427−0.870). Subgroup analyses indicated that the mortality benefit was particularly evident in females (HR 0.585, 95% CI: 0.379−0.901) and those aged 65 years and older (HR 0.500, 95% CI: 0.301−0.806). In patients with immune-mediated inflammatory diseases receiving JAKi, RZV vaccination is associated with a 39% reduction in all-cause mortality compared to unvaccinated individuals. RZV vaccination should be considered for this high-risk population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dendritic cells and the exosomes they secrete play a crucial role in the immune system, and studies have shown that dendritic cell function is dramatically reduced in patients with chronic hepatitis B. Alcohol could stimulate dendritic cell maturation. Consequently, the present work explored the therapeutic effect of alcohol-induced dendritic cells and their exosomes in hepatitis B virus (HBV) infection. We systematically investigated the functional effects of alcohol stimulation and HBV infection on dendritic cells and their exosomes, as well as cocultured alcohol-induced dendritic cells and exosomes with lymphocytes from HBV transgenic mice and chronic hepatitis B patients to study the T cell immune response. Our findings revealed that alcohol significantly accelerated the maturation of bone marrow-derived dendritic cells in mice and dendritic cells in patients with chronic hepatitis B, but had no effect on the DC2.4 cell line. Simultaneously, HBV infection was demonstrated to inhibit dendritic cell activation and maturation, as well as exosomes. More importantly, alcohol-induced dendritic cells enhanced T-cell immunity in HBV transgenic mice and chronic hepatitis B patients, and their exosomes had the same impact. The maturation of dendritic cells and their exosomes can be effectively induced by alcohol. Meanwhile, alcohol-induced maturation of dendritic cells and exosomes can significantly repair the poor T-cell immunity caused by HBV infection, making it a promising novel treatment for chronic hepatitis B patients in the future.
{"title":"Alcohol-Induced Dendritic Cells and Their Exosomes Promote T-Cell Immunity in Hepatitis B Virus Transgenic Mice and Patients With Chronic Hepatitis B","authors":"Xingzhong Miao, Xiaoshuang Zhou, Chaonan Liu, Honglin Shi, Fang Liu, Yingmin Ma, Hongbo Shi","doi":"10.1002/jmv.70287","DOIUrl":"https://doi.org/10.1002/jmv.70287","url":null,"abstract":"<div>\u0000 \u0000 <p>Dendritic cells and the exosomes they secrete play a crucial role in the immune system, and studies have shown that dendritic cell function is dramatically reduced in patients with chronic hepatitis B. Alcohol could stimulate dendritic cell maturation. Consequently, the present work explored the therapeutic effect of alcohol-induced dendritic cells and their exosomes in hepatitis B virus (HBV) infection. We systematically investigated the functional effects of alcohol stimulation and HBV infection on dendritic cells and their exosomes, as well as cocultured alcohol-induced dendritic cells and exosomes with lymphocytes from HBV transgenic mice and chronic hepatitis B patients to study the T cell immune response. Our findings revealed that alcohol significantly accelerated the maturation of bone marrow-derived dendritic cells in mice and dendritic cells in patients with chronic hepatitis B, but had no effect on the DC2.4 cell line. Simultaneously, HBV infection was demonstrated to inhibit dendritic cell activation and maturation, as well as exosomes. More importantly, alcohol-induced dendritic cells enhanced T-cell immunity in HBV transgenic mice and chronic hepatitis B patients, and their exosomes had the same impact. The maturation of dendritic cells and their exosomes can be effectively induced by alcohol. Meanwhile, alcohol-induced maturation of dendritic cells and exosomes can significantly repair the poor T-cell immunity caused by HBV infection, making it a promising novel treatment for chronic hepatitis B patients in the future.</p></div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Li, H. Yan, J. Li, et al., “Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection,” Journal of Medical Virology 97, no. 2 (2025):e70189. doi: 10.1002/jmv.70189.
In the article referenced above, there was an error in the title. The title was incorrectly labeled as “Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection.” The correct title should read: “Low Neutralization of SARS-CoV-2 Omicron BA.5.2.48, XBB.1.5 and JN.1 by Homologous Booster and Breakthrough Infection.”
Additionally, in the “Materials and Methods” section, there was an error in the Virus Stocks part. The virus stock was incorrectly labeled as “SARS-CoV-2/E6/FJH/2022/ZJ104 (Omicron/BA.5.2).” The correct label should read: “SARS-CoV-2/E6/FJH/2022/ZJ104 (Omicron/BA.5.2.48).”
We apologize for this error.
{"title":"Correction to “Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection”","authors":"","doi":"10.1002/jmv.70271","DOIUrl":"https://doi.org/10.1002/jmv.70271","url":null,"abstract":"<p>J. Li, H. Yan, J. Li, et al., “Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection,” <i>Journal of Medical Virology</i> 97, no. 2 (2025):e70189. doi: 10.1002/jmv.70189.</p><p>In the article referenced above, there was an error in the title. The title was incorrectly labeled as “Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection.” The correct title should read: “Low Neutralization of SARS-CoV-2 Omicron BA.5.2.48, XBB.1.5 and JN.1 by Homologous Booster and Breakthrough Infection.”</p><p>Additionally, in the “Materials and Methods” section, there was an error in the Virus Stocks part. The virus stock was incorrectly labeled as “SARS-CoV-2/E6/FJH/2022/ZJ104 (Omicron/BA.5.2).” The correct label should read: “SARS-CoV-2/E6/FJH/2022/ZJ104 (Omicron/BA.5.2.48).”</p><p>We apologize for this error.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70271","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Masako Shimamura, Juhyeong Kim, Alexandra K. Medoro, Kaitlyn Flint, Irina Kaptsan, Huanyu Wang, Traci Pifer, Rachelle Harris, José Cuartas, Amy Leber, Pablo J. Sánchez
Congenital cytomegalovirus (cCMV) infection is diagnosed by positive urine or saliva testing within 21 days after birth. Beyond this age, newborn dried blood spot (DBS) PCR can retrospectively diagnose cCMV infection but has lower sensitivity than urine or saliva PCR testing. The DBS PCR may be negative due to the absence of blood DNAemia at birth or to the technical limit of detection for DBS PCR. The objective of this study was to distinguish these two possibilities by determining agreement between DBS and plasma CMV PCR tests among cCMV-infected infants. This single center retrospective cohort study evaluated 70 cCMV-infected infants diagnosed by a positive urine CMV PCR, who had a CMV DBS at birth and a plasma PCR test within 31 days after birth. Clinical characteristics and viral loads were compared between groups according to paired DBS and plasma PCR results. Test agreement was calculated using Cohen's kappa coefficient. The DBS PCR sensitivity was 71% compared to urine PCR. Of the 70 subjects, 49 (70%) subjects were DBS+ /plasma+ , 1 (1.4%) were DBS+ /plasma−, 14 (20%) were DBS−/plasma+ , and 6 (9%) were DBS−/plasma−. Agreement between the tests was fair (κ = 0.348, 95% CI 0.115-0.581). Of the 20 subjects with DBS− tests, 6 (30%) had undetectable plasma DNAemia. Of the infants with DBS−/plasma+ PCR, plasma viral loads were significantly lower than infants with DBS+ /plasma+ PCR testing. Nearly a third of cCMV infected infants may be missed by DBS testing due to both biological and technical limitations of this method.
{"title":"Agreement Between Dried Blood Spot and Plasma PCR in Infants With Congenital Cytomegalovirus Infection","authors":"Masako Shimamura, Juhyeong Kim, Alexandra K. Medoro, Kaitlyn Flint, Irina Kaptsan, Huanyu Wang, Traci Pifer, Rachelle Harris, José Cuartas, Amy Leber, Pablo J. Sánchez","doi":"10.1002/jmv.70257","DOIUrl":"https://doi.org/10.1002/jmv.70257","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 <p>Congenital cytomegalovirus (cCMV) infection is diagnosed by positive urine or saliva testing within 21 days after birth. Beyond this age, newborn dried blood spot (DBS) PCR can retrospectively diagnose cCMV infection but has lower sensitivity than urine or saliva PCR testing. The DBS PCR may be negative due to the absence of blood DNAemia at birth or to the technical limit of detection for DBS PCR. The objective of this study was to distinguish these two possibilities by determining agreement between DBS and plasma CMV PCR tests among cCMV-infected infants. This single center retrospective cohort study evaluated 70 cCMV-infected infants diagnosed by a positive urine CMV PCR, who had a CMV DBS at birth and a plasma PCR test within 31 days after birth. Clinical characteristics and viral loads were compared between groups according to paired DBS and plasma PCR results. Test agreement was calculated using Cohen's kappa coefficient. The DBS PCR sensitivity was 71% compared to urine PCR. Of the 70 subjects, 49 (70%) subjects were DBS+ /plasma+ , 1 (1.4%) were DBS+ /plasma−, 14 (20%) were DBS−/plasma+ , and 6 (9%) were DBS−/plasma−. Agreement between the tests was fair (κ = 0.348, 95% CI 0.115-0.581). Of the 20 subjects with DBS− tests, 6 (30%) had undetectable plasma DNAemia. Of the infants with DBS−/plasma+ PCR, plasma viral loads were significantly lower than infants with DBS+ /plasma+ PCR testing. Nearly a third of cCMV infected infants may be missed by DBS testing due to both biological and technical limitations of this method.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70257","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), syphilis, hepatitis B and hepatitis C are the four major Mother-to-child transmission (MTCT) diseases, represent a significant public health challenge worldwide. Understanding the disease burden among women of child-bearing age (WCBA) helps to implement effective screening and treatment programs to control the MTCT diseases globally. Data on HIV/AIDS, syphilis, hepatitis B, and hepatitis C was collected from the Global Burden of Disease (GBD) 2021 database spanning 1992–2021. We analyzed the temporal trends of four MTCT diseases with joinpoint regression and further evaluated age-period-cohort effects using the age-period-cohort model. The age-standardized incidence rates per 100,000 population for HIV/AIDS, syphilis, hepatitis B, and hepatitis C in 2021 were 34.73 (95% uncertainty interval [UI]: 30.03, 40.54), 279.19 (95% UI: 174.59, 459.54), 908.39 (95% UI: 494.99, 1640.44), and 77.44 (95% UI: 41.57, 126.12). Joinpoint regression revealed ongoing declines in HIV/AIDS and hepatitis B rates among WCBA, contrasting with increasing trends for hepatitis C and syphilis post-2012. Age effects for HIV/AIDS, syphilis, and hepatitis B peaked in the 15–29 age group, while hepatitis C peaked in the 45–49 age group. Period effects showed increased incidence rates for syphilis and hepatitis C since 2012, peaking between 2017–2021, while HIV/AIDS and hepatitis B showed a general decline. Cohort effects for all four diseases generally followed a fluctuating downward trend. For hepatitis B, the incidence rate is declining in all 21 GBD regions. At national level, only the United Kingdom and Greece have seen a slight increase in incidence rates compared to 30 years ago, but the increase is minimal. For other MTCT diseases, Eastern Europe has the highest increase in incidence rates of HIV/AIDS and hepatitis C among WCBA, which requires special attention. Tropical Latin America is the region with the greatest increase in syphilis incidence rates. Specifically, at the national level, the countries with the highest increase in incidence rates for HIV/AIDS, syphilis, and hepatitis C are Pakistan, Greece, and Ukraine, respectively. Globally, while HIV/AIDS and hepatitis B incidence in WCBA has decreased, negative age, period, and cohort effects persist in certain countries. Post-2012, hepatitis C and syphilis incidence in WCBA has risen, underscoring the need to refine management strategies against MTCT diseases.
{"title":"Global Temporal Trends in Mother-to-Child Transmission Disease Incidence Among Women of Child-Bearing Age: An Analysis of Global Burden of Disease Study 2021 Data","authors":"Qiubai Jin, Mingxiao Zhou, Meiqi Sun, Bobiao Ning, Mingyue Liu, Shuanglin Zhou, Ping Song","doi":"10.1002/jmv.70283","DOIUrl":"https://doi.org/10.1002/jmv.70283","url":null,"abstract":"<div>\u0000 \u0000 <p>Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), syphilis, hepatitis B and hepatitis C are the four major Mother-to-child transmission (MTCT) diseases, represent a significant public health challenge worldwide. Understanding the disease burden among women of child-bearing age (WCBA) helps to implement effective screening and treatment programs to control the MTCT diseases globally. Data on HIV/AIDS, syphilis, hepatitis B, and hepatitis C was collected from the Global Burden of Disease (GBD) 2021 database spanning 1992–2021. We analyzed the temporal trends of four MTCT diseases with joinpoint regression and further evaluated age-period-cohort effects using the age-period-cohort model. The age-standardized incidence rates per 100,000 population for HIV/AIDS, syphilis, hepatitis B, and hepatitis C in 2021 were 34.73 (95% uncertainty interval [UI]: 30.03, 40.54), 279.19 (95% UI: 174.59, 459.54), 908.39 (95% UI: 494.99, 1640.44), and 77.44 (95% UI: 41.57, 126.12). Joinpoint regression revealed ongoing declines in HIV/AIDS and hepatitis B rates among WCBA, contrasting with increasing trends for hepatitis C and syphilis post-2012. Age effects for HIV/AIDS, syphilis, and hepatitis B peaked in the 15–29 age group, while hepatitis C peaked in the 45–49 age group. Period effects showed increased incidence rates for syphilis and hepatitis C since 2012, peaking between 2017–2021, while HIV/AIDS and hepatitis B showed a general decline. Cohort effects for all four diseases generally followed a fluctuating downward trend. For hepatitis B, the incidence rate is declining in all 21 GBD regions. At national level, only the United Kingdom and Greece have seen a slight increase in incidence rates compared to 30 years ago, but the increase is minimal. For other MTCT diseases, Eastern Europe has the highest increase in incidence rates of HIV/AIDS and hepatitis C among WCBA, which requires special attention. Tropical Latin America is the region with the greatest increase in syphilis incidence rates. Specifically, at the national level, the countries with the highest increase in incidence rates for HIV/AIDS, syphilis, and hepatitis C are Pakistan, Greece, and Ukraine, respectively. Globally, while HIV/AIDS and hepatitis B incidence in WCBA has decreased, negative age, period, and cohort effects persist in certain countries. Post-2012, hepatitis C and syphilis incidence in WCBA has risen, underscoring the need to refine management strategies against MTCT diseases.</p>\u0000 </div>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"97 3","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号